Payton Nyquvest had a history of trauma that resulted in deep depression. He tried every form of therapy and meds, and was considering ending his life when he tried Ayahuasca. The experience was guided, reassuring, and transformative. Payton devoted his life to understanding psychedelics and empowering people to heal and be well through the development and delivery of psychedelic medicine and integration.

Payton is the Co-founder and CEO of Numinus, a company that engages in both the research for psychedelics and the commercialized expansion of the sector. Payton has deep business leadership experience, particularly in the finance sector, and is a recognized innovator and visionary in mental health care.